Explore 3 Stock Ideas & Industry Insights Download Free Report

Aimei Health Technology Co., Ltd Ordinary Share

Company price
12.39 USD 0.36 ( 2.99%)
Last update at 2026-11-10T14:45:00Z
VOLUME
740
Market Cap
249.77M
P/E
204.00

Momentum Score

…

Aimei Health Technology Co., Ltd does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to acquire small cap businesses in the biopharmaceutical, medical technology and device industries, as well as in the diagnostic and other services sector. Aimei Health Technology Co., Ltd was incorporated in 2023 and is based in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
12.29
Low
12.39
High
52 Week Price Range
6.75
Low
130.37
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Aimei Health Technology Co., Ltd (AFJK) is a U.S.-listed health-technology company focused on serving healthcare markets in China, although public disclosures offer limited operational detail. Long-term growth drivers that may benefit the company include China's aging population, rising healthcare demand and wider adoption of digital health solutions, so investors may find exposure to domestic healthcare digitization attractive if execution succeeds.
Most important investment risks include regulatory and cross-border listing uncertainty for Chinese issuers, low trading liquidity, and execution and financing risks that could materially impair operations.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
12.03
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-
Net Debt
0.20M
ROCE
-1.46%
Diluted EPS TTM
0.20

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31
Type yearly yearly
Date 2024-12-31 2023-12-31
Income before tax 2.55M 0.17M
Net income 2.55M 0.17M
Ebit -1.06M 0.17M
Ebitda -1.06M 0.17M
Depreciation and amortization - 0.20M
Operating income -1.06M -0.03M
Other operating expenses 1.06M 0.03M
Interest income 3.62M -
Net interest income 3.62M -
Income tax expense 2.55M 0.17M
Total revenue 0.00M -
Total operating expenses 1.06M 0.03M
Total other income expense net 3.62M 0.20M
Net income from continuing ops 2.55M -
Breakdown 2024-12-31 2023-12-31
Type yearly yearly
Date 2024-12-31 2023-12-31
Total assets 73.81M 70.47M
Other current assets 0.00M -
Total liab 1.51M 0.71M
Total stockholder equity 72.31M 69.76M
Other current liab 0.59M 0.02M
Common stock 73.78M 69.89M
Capital stock 73.78M 69.89M
Retained earnings -1.48M -0.13M
Other assets - 0.00M
Cash 0.03M 0.58M
Total current liabilities 0.82M 0.02M
Net debt 0.20M -0.58M
Short term debt 0.23M -
Short long term debt 0.23M -
Short long term debt total 0.23M -
Other stockholder equity -73.78M -
Total current assets 0.03M 0.58M
Short term investments - 69.89M
Non currrent assets other 73.78M 69.89M
Non current assets total 73.78M 69.89M
Breakdown 2024-12-31 2023-12-31
Type yearly yearly
Date 2024-12-31 2023-12-31
Investments -0.28M -
Total cashflows from investing activities -0.28M -69.69M
Net borrowings 0.28M -
Total cash from financing activities 0.40M 70.27M
Net income 2.55M 0.17M
Change in cash -0.55M 0.58M
Begin period cash flow 0.58M -
End period cash flow 0.03M 0.58M
Total cash from operating activities -0.67M -
Issuance of capital stock 0.00M -
Other cashflows from investing activities -0.28M -
Other cashflows from financing activities 0.12M 70.27M
Capital expenditures 0.00M 0.00M
Change in working capital 0.39M 0.02M
Other non cash items -3.62M -0.20M
Free cash flow -0.67M -

Peer Comparison*

Sector: Financial Services Industry: Shell Companies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
AFJK
Aimei Health Technology Co., Ltd Ordinary Share
0.36
2.99%
12.39 204.00 - - 5.95
CLUS
CLUS
-
-%
200.00 - - 0.09 0.92
SGDH
Sgd Holdings Ltd
-
-%
0.11 - - 59741.55 0.56
LION
Lionsgate Studios Holding Corp.
-0.03
0.18%
14.21 - 23.31 1.13 1.35
QKIE
QKIE
0.44
29.33%
1.94 - - 470.20 -

Profile*

Aimei Health Technology Co., Ltd Ordinary Share

Aimei Health Technology Co., Ltd does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to acquire small cap businesses in the biopharmaceutical, medical technology and device industries, as well as in the diagnostic and other services sector. Aimei Health Technology Co., Ltd was incorporated in 2023 and is based in New York, New York.

10 East 53rd Street, New York, NY, United States, 10022

861 375 8131392

Name Title Year Born
Mr. Junheng Xie CEO, Secretary & Director 1989
Mr. Heung Ming Wong CFO & Director 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…